Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 67 (2 Pt A), 95-106

Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies

Affiliations
Review

Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies

Christoph Spiess et al. Mol Immunol.

Abstract

Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they were first described. Two bispecific antibodies, catumaxomab (Removab(®), anti-EpCAM×anti-CD3) and blinatumomab (Blincyto(®), anti-CD19×anti-CD3) are approved for therapy, and >30 additional bispecific antibodies are currently in clinical development. Many of these investigational bispecific antibody drugs are designed to retarget T cells to kill tumor cells, whereas most others are intended to interact with two different disease mediators such as cell surface receptors, soluble ligands and other proteins. The modular architecture of antibodies has been exploited to create more than 60 different bispecific antibody formats. These formats vary in many ways including their molecular weight, number of antigen-binding sites, spatial relationship between different binding sites, valency for each antigen, ability to support secondary immune functions and pharmacokinetic half-life. These diverse formats provide great opportunity to tailor the design of bispecific antibodies to match the proposed mechanisms of action and the intended clinical application.

Keywords: Antibody engineering; Antibody therapeutics; Bispecific antibodies.

Similar articles

See all similar articles

Cited by 138 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback